GB-115: solid dosage form — RU2602742C2
Сергей Борисович Середенин, Татьяна Александровна Гудашева, Борис Михайлович Пятин, Нина Ивановна Авдюнина, Константин Викторович Алексеев, Любовь Николаевна Грушевская, Лариса Геннадьевна Колик, Владимир Павлович Жердев, Надежда Михайловна Зайцева, Евгения Викторовна Блынская, Ксения Геннадьевна Турчинская, Наталья Викторовна Тихонова, Людмила Михайловна Гаевая, Марк Александрович Константинопольский, Светлана Семеновна Бойко · 2016 · RU2602742C2 · patent family RU2602742C2
Published 2016-11-20.
Reported patent results
Reported findings
The solid formulation produced higher measured exposure and a longer circulating profile in the reported animal comparison.
GB-115 solid-form versus unformulated-substance pharmacokinetics in rats, with behavioral comparisons.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Relative bioavailability | 192% relative to the reference substance | A formulation-specific rat ratio; not absolute oral bioavailability or a human value |
| Elimination and residence | Half-life 44.75 minutes; mean residence time 68.32 minutes; elimination constant 0.0155/min | Parameters reported for the formulation · Rat pharmacokinetics |
| Time profile | A second maximum described around 40–60 minutes; detectable through 90 minutes | The proposed recirculation explanation is not directly proven |
Rat exposure and behavior do not establish a superior human anxiolytic effect. The pharmacokinetic values cannot be transferred to a different product.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The claims concern a solid pharmaceutical form of GB-115 and formulation components.
Formulation protection is distinct from proof of clinical benefit or from the base-compound discovery claim.
- Publication
- RU2602742C2 ↗ · 2016-11-20
- Earliest priority / filing
- 2013-12-13 / 2013-12-13
- Original applicant / assignee
- Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имен В.В. Закусова"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition of n-(6-phenylhexanoyl)glycyl-l-tryptophan amide in solid dosage form
Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Константин Викторович Алексеев; Любовь Николаевна Грушевская; Лариса Геннадьевна Колик; Владимир Павлович Жердев; Надежда Михайловна Зайцева; Евгения Викторовна Блынская; Ксения Геннадьевна Турчинская; Наталья Викторовна Тихонова; Людмила Михайловна Гаевая; Марк Александрович Константинопольский; Светлана Семеновна Бойко.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Formulation protection is distinct from proof of clinical benefit or from the base-compound discovery claim.
- Rat exposure and behavior do not establish a superior human anxiolytic effect. The pharmacokinetic values cannot be transferred to a different product.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-RU2602742C2. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Сергей Борисович Середенин, Татьяна Александровна Гудашева, Борис Михайлович Пятин, Нина Ивановна Авдюнина, Константин Викторович Алексеев, Любовь Николаевна Грушевская, Лариса Геннадьевна Колик, Владимир Павлович Жердев, Надежда Михайловна Зайцева, Евгения Викторовна Блынская, Ксения Геннадьевна Турчинская, Наталья Викторовна Тихонова, Людмила Михайловна Гаевая, Марк Александрович Константинопольский, Светлана Семеновна Бойко. GB-115: solid dosage form — RU2602742C2 RU2602742C2 · patent family RU2602742C2 2016.
Molekul research summary: https://molekul.io/research/patent-ru2602742c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry